Mingyao Liu

MemberContent

homepage INFO MemberContent

Mingyao Liu

	Mingyao Liu
	Nationally-endowed professor，
	Director, Istitute of Biomedical Sciences
	East China Normal University, Shanghai

Dr. Mingyao Liu received his PhD degree in the University of Maryland College Park (1992), did his postdoctoral training and fellowship in John Hopkins University School of Medicine and California Institute of Technology (Caltech) (from 1993-1998), respectively. He started his independent lab as an assistant professor in 1999 at the Institute of Biosciences and Technology, Texas A&M University and was promoted to tenured full professor in 2006. He was the Dean of the School of Life Sciences, East China Normal University from 2012-2020. Now he is the nationally-endowed professor and the Director of Institute of Biomedical Sciences in East China Normal University, Shanghai. He is also the founder and Chairman of Shanghai BRL Medicine Inc. and two other biotech companies.

Dr. Liu's research interests focus on GPCR signaling, gene editing and cell therapy. He has published more than 450 research papers in top journals, such as Science、Nature、Cell、Nature Medicine、Nature Biotechnology, etc. He has won the First Prize of National Science and Technology Progress Award in 2012, the First Prize of Shanghai Science and Technology Progress Award in 2017 and 2024, the Shanghai Magnolia Memorial Award in 2014, the Outstanding Academic Contribution Award of East China Normal University in 2021, and The 8th Outstanding Contribution Award for Translational Medicine in 2025.

Publication

1. Du B, Qin J, Lin B, Zhang J, Li D, Liu M. CAR‑T therapy in solid tumors. Cancer Cell. 2025 Apr 14;43 (4):665‑679.

2. Li H, Qiu Y, Song B, Quan X, Zhang D, Li X, Yang J, Liu X, Zeng Z, Jing J, Yin S, Dai Q, Wang L, Han H, Ye H, Sun Z, Cheng Y, Zhang X, Du B, Liu M, Li D. Engineering a photoactivatable A‑to‑I RNA base editor for gene therapy in vivo. Nature Biotechnology. 2026 Feb;44 (2).

3. Yang C, Sun C, Tan B, Hu C, Wan L, Wang C, Shi X, Qin J, Zhang N, Zheng B, Liu M, Lin J, Du B, Tong H. Allogeneic anti‑CD19 CAR‑T cells induce remission in refractory systemic lupus erythematosus. Cell Res. 2025 Aug;35 (8):607‑609.

4. He J, Chai X, Zhang Q, Wang Y, Wang Y, Yang X, Wu J, Feng B, Sun J, Rui W, Ze S, Fu Y, Zhao Y, Zhang Y, Zhang Y, Liu M, Liu C, She M, Hu X, Ma X, Yang H, Li D, Zhao S, Li G, Zhang Z, Tian Z, Ma Y, Cao L, Yi B, Li D, Nussinov R, Eng C, Chan T, Ruppin E, Gutkind J, Cheng F, Liu M, Lu W. The lactate receptor HCAR1 drives the recruitment of immunosuppressive PMN‑MDSCs in colorectal cancer. Nature Immunology. 2025 Mar;26 (3).

5. Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L, Xiao Y, Sun A, Wan X, Liu S, Liu Y, Ta N, Zhang H, Song J, Li T, Zhou L, Yin J, Ye L, Lu H, Hong J, Cheng H, Wang P, Li W, Chen J, Zhang J, Luo J, Huang M, Guo L, Pan X, Jin Y, Ye W, Dai L, Zhu J, Sun L, Zheng B, Li D, He Y, Liu M, Wu H, Du B, Xu H. Allogeneic CD19‑targeted CAR‑T therapy in patients with severe myositis and systemic sclerosis. Cell. 2024 Sep 5;187 (18):4890‑4904.e9.

6. Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, Zhang L, Wei G, Tian Y, Zhao K, Chen A, Tan B, Cui J, Li D, Li Y, Qi Y, Wang D, Wu Y, Li D, Du B, Liu M, Huang H. Non‑viral, specifically targeted CAR‑T cells achieve high safety and efficacy in B‑NHL. Nature. 2022 Sep;609 (7926):369‑374.

7. Zhang J, Du B, Liu M. Let's turn the CAR‑T cells ON and OFF precisely. Cancer Cell. 2022 Nov 14;40 (11):1264‑1266.

8. Chen L, Zhu B, Ru G, Meng H, Yan Y, Hong M, Zhang D, Luan C, Zhang S, Wu H, Gao H, Bai S, Li C, Ding R, Xue N, Lei Z, Chen Y, Guan Y, Siwko S, Cheng Y, Song G, Wang L, Yi C, Liu M, Li D. Re‑engineering the adenine deaminase TadA‑8e for efficient and specific CRISPR‑based cytosine base editing. Nature Biotechnology. 2023 May;41 (5):663‑+.

9. Fu B, Liao J, Chen S, Li W, Wang Q, Hu J, Yang F, Hsiao S, Jiang Y, Wang L, Chen F, Zhang Y, Wang X, Li D, Liu M, Wu Y. CRISPR‑Cas9‑mediated gene editing of the BCL11A enhancer for pediatric β0/β0 transfusion‑dependent β‑thalassemia. Nature Medicine. 2022 Aug;28 (8):1573‑+.

10. Luo J, Yang Z, Ma Y, Yue Z, Lin H, Qui G, Huang J, Dai W, Li C, Zheng C, Xu L, Chen H, Wang J, Li D, Siwko S, Penninger J, Ning G, Xiao J, Liu M. LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. Nature Medicine. 2016 May;22 (5):539‑546.

2017-10-31